Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular Divisions Boost Medtronic's FYQ2 Top-Line As Hurricane Recovery Continues

Executive Summary

Medtronic's revenue of $7.1bn for the second fiscal quarter of 2018 was down 4% year-over-year on an as-reported basis, but up 4% on a comparable constant-currency basis. –It would have been even greater if not for the hurricane that hindered manufacturing operations in Puerto Rico, the company reported Nov 21.

You may also be interested in...



TAVR Update: Edwards Delays European Launch Of Sapien 3 Ultra; New Medtronic CoreValve Data

Global Approvals Analysis: Emerging Markets Drive Volume Of OUS Approvals

The numbers of medical device approvals were up in most regions outside the US and the biggest surge, by percentage, was in approvals from emerging markets and the so-called BRIC countries. It remains to be seen if the trend will continue in 2018, but many companies are already counting on important non-US approvals coming in the next year.

Medtronic Lowers Hurricane Maria Cost Estimates

Recovery from the hurricane, which devastated four Medtronic facilities located on Puerto Rico, is projected to cost $50m to $60m, according to a preliminary second-quarter earnings estimate from the firm. Last month, the company suggested costs could be as high as $250m.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT121801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel